{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:49:35Z","timestamp":1788389375797,"version":"build-2803163510"},"reference-count":78,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2024,6,12]]},"DOI":"10.1080\/14656566.2024.2372453","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T08:03:11Z","timestamp":1719388991000},"page":"1175-1186","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Recent advances in JAK2 inhibition for the treatment of myelofibrosis"],"prefix":"10.1080","volume":"25","author":[{"given":"Noa","family":"Rippel","sequence":"first","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kremyanskaya","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,7]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0236-2"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017578"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.06.014"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.11.001"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.02.031"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9867"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062188"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26050"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-785923"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.148"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-783225"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0527-7"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17727"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25777"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002970"},{"key":"#cr-split#-e_1_3_4_20_1.1","unstructured":"A Phase 3 study of pacritinib in patients with primary myelofibrosis post polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis (PACIFICA) clinicaltrials gov. [cited Updated 2024 Apr 5"},{"key":"#cr-split#-e_1_3_4_20_1.2","unstructured":"cited 2024 Apr 27]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03165734"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01029-3"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01637-7"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02036-0"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740092"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-20-35"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27033"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26709"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7062"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967760.70775.53"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178956"},{"key":"e_1_3_4_33_1","unstructured":"A clinical trial of tq05105 tablets in the treatment of moderate and high risk myelofibrosis. Available from: www.classic.clinicaltrials.gov\/ct2\/show\/NCT05020652"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11303"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.06.006"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162621"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179369"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019580"},{"key":"e_1_3_4_39_1","unstructured":"A study to evaluate the safety tolerability and pharmacokinetics of INCB160058 when administered orally to healthy adult participant clinicaltrials gov. [cited 2024 Mar 21]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06213818"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.05.016"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.11.009"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01972"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970976.05785.80"},{"key":"e_1_3_4_44_1","first-page":"628","volume-title":"65th ASH Annual Meeting and Exposition","author":"Rampal RK","unstructured":"Rampal RK, Grosicki S, Chraniuk D, et al. Pelabresib in combination with ruxolitinib for janus kinase inhibitor treatment-na\u00efve patients with myelofibrosis: results of the manifest-2 randomized, double-blind, phase 3 Study. In: 65th ASH Annual Meeting and Exposition. 2023 Nov 28; San Diego (CA): Blood. p. 628."},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0484"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.1.90"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.319"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018022012"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02864"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0235"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126189"},{"key":"e_1_3_4_52_1","unstructured":"A Study to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Participants with Myelofibrosis ClinicalTrials gov. [cited 2023 Dec 11]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05371964"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5836"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15730"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00116-8"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.10.038"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02188"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173509"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.01.020"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-410712"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.313"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970868.28141.7f"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967752.72578.ff"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.2174\/13816128113199990611"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00442-4"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-186674"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180134"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7063"},{"key":"e_1_3_4_69_1","unstructured":"Rosa K. FDA grants fast track status to selinexor for myelofibrosis: OncLive. [cited 2023 Jul 19]. Available from: www.onclive.com\/view\/fda-grants-fast-track-status-to-selinexor-for-myelofibrosis"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1133"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-876888"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178012"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967580.08826.11"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01234-X"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34103"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.08.022"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)01822-X"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7018"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2024.2372453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T22:54:43Z","timestamp":1727218483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2024.2372453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":78,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,6,12]]}},"alternative-id":["10.1080\/14656566.2024.2372453"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2024.2372453","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}